Mobilization of peripheral blood progenitor cells for autografting: chemotherapy and G-CSF or GM-CSF.

The mobilization of haematopoietic progenitor cells is a multifactorial process, still poorly understood at the molecular level. Mobilized haematopoietic progenitors, as defined by the expression of CD34 cell surface molecule, comprise heterogeneous subpopulations of cells committed to different haematopoietic lineages. Haematopoietic progenitors may be mobilized by chemotherapy alone, haematopoietic growth factors alone, or by chemotherapy plus haematopoietic growth factors. The choice of a mobilization regimen that allows an optimal yield of progenitors with a minimum number of leukaphereses should incorporate, in most patients, a disease-specific chemotherapeutic agent(s) plus a haematopoietic growth factor, to be continued until completion of harvest.

[1]  L. To,et al.  Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF , 1998, Bone Marrow Transplantation.

[2]  H. Goldschmidt,et al.  Recombinant human granulocyte and granulocyte–macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells , 1998, Bone Marrow Transplantation.

[3]  D. Catovsky,et al.  The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue , 1998, Bone Marrow Transplantation.

[4]  A. Weaver,et al.  Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy , 1998, Bone Marrow Transplantation.

[5]  G. Gleim,et al.  CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Barlogie,et al.  Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Kröger,et al.  Schedule-dependency of granulocyte colony-stimulating factor in peripheral blood progenitor cell mobilization in breast cancer patients. , 1998, Blood.

[8]  B. McAneny,et al.  Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim , 1998, British journal of haematology.

[9]  D. Linch,et al.  Optimal timing for collection of PBPC after glycosylated G-CSF administration , 1998, Bone Marrow Transplantation.

[10]  A. Palumbo,et al.  Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high‐dose chemotherapy courses , 1997, British journal of haematology.

[11]  M. Aapro,et al.  A European perspective on haematopoietic growth factors in haemato-oncology: report of an expert meeting of the EORTC. , 1997, European journal of cancer.

[12]  J. Hainsworth,et al.  Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte‐colony‐ stimulating factor: an analysis of 497 patients , 1997, Transfusion.

[13]  D. Linch,et al.  Crossover study of the haematological effects and pharmacokinetics of glycosylated and non‐glycosylated G‐CSF in healthy volunteers , 1997, British journal of haematology.

[14]  R. Arranz,et al.  Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone , 1997, Bone Marrow Transplantation.

[15]  R. Fanin,et al.  Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. , 1997, Blood.

[16]  C. Scott,et al.  Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. , 1997, Blood.

[17]  R. Storb,et al.  Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Copelan,et al.  Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  F. Ortuño,et al.  Prospective Randomized Study Comparing the Efficacy of Bioequivalent Doses of glycosylated and nonglycosylated rG‐CSF for Mobilizing Peripheral Blood Progenitor Cells , 1997, British journal of haematology.

[20]  I. Tabbara,et al.  The role of granulocyte colony-stimulating factor in hematopoietic stem cell transplantation. , 1997, Cancer investigation.

[21]  T. Springer,et al.  Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  A. Howell,et al.  Mobilisation kinetics of primitive haemopoietic cells following G-CSF with or without chemotherapy for advanced breast cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  N. Ferrara,et al.  Vascular endothelial growth factor. , 1996, European journal of cancer.

[24]  D. Crowther,et al.  Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor. , 1996, Blood.

[25]  G. Koumakis,et al.  Peripheral blood progenitor cell (PBPC) transplantation with a single apheresis in patients with lymphoma, myeloma and solid tumors , 1996, European journal of haematology.

[26]  K. J. Nielsen,et al.  Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells. , 1996, Journal of hematotherapy.

[27]  P. Pedrazzoli,et al.  Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. , 1996, Anticancer research.

[28]  H. Goldschmidt,et al.  Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. , 1996, Bone marrow transplantation.

[29]  S. Rodenhuis,et al.  Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Kröger,et al.  Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. , 1996, Bone marrow transplantation.

[31]  T. Nakahata,et al.  Characterization of peripheral blood progenitor cells (PBPC) mobilized by filgrastim (rHuG‐CSF) in normal volunteers: dose–effect relationship for filgrastim with the character of mobilized PBPC , 1996, British journal of haematology.

[32]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[33]  G. Bonadonna,et al.  Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  K. Takenaka,et al.  G-CSF-induced mobilization of peripheral blood stem cells from healthy adults for allogeneic transplantation. , 1996, Journal of hematotherapy.

[35]  R. Bataille,et al.  G‐CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma , 1996, British journal of haematology.

[36]  J. Winter,et al.  Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Roberts,et al.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.

[38]  R. Möhle,et al.  Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. , 1995, Experimental hematology.

[39]  C. Craddock,et al.  The VLA4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[41]  C. Begley,et al.  Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  M. Vadas,et al.  Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins , 1995, The Journal of experimental medicine.

[43]  L. Terstappen,et al.  Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. , 1995, Blood.

[44]  L. To,et al.  A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells. , 1994, Blood.

[45]  A. Nademanee,et al.  High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  S. Asano,et al.  A time course study for optimal harvest of peripheral blood progenitor cells by granulocyte colony-stimulating factor in healthy volunteers. , 1994, Experimental hematology.

[47]  C. Nissen,et al.  In Vitro Comparison of the Biological Potency of Glycosylated versus Nonglycosylated rG-CSF , 1994 .

[48]  J. Armitage,et al.  High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. , 1994, Blood.

[49]  T. Papayannopoulou,et al.  Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. Strippoli,et al.  Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s) , 1993, Stem cells.

[51]  H. Goldschmidt,et al.  Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF. , 1993, Experimental hematology.

[52]  G. Rosner,et al.  Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. , 1993, Blood.

[53]  P. Mauch,et al.  Mobilization of hematopoietic stem and progenitor cell subpopulations from the marrow to the blood of mice following cyclophosphamide and/or granulocyte colony-stimulating factor. , 1993, Blood.

[54]  H. Goldschmidt,et al.  Autologous blood progenitor cell transplantation in relapsed Hodgkin's disease--the role of haematopoietic growth factors. , 1993, Bone marrow transplantation.

[55]  C. Begley,et al.  Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. , 1992, British Journal of Cancer.

[56]  L. To,et al.  Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation. , 1992, Bone marrow transplantation.

[57]  G. Demetri,et al.  Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. , 1992, Blood.

[58]  G. Fritsch,et al.  Report on the European Workshop on Peripheral Blood Stem Cell Determination and Standardization--Mulhouse, France, February 6-8 and 14-15, 1992. , 1992, Journal of hematotherapy.

[59]  L. Schwartzberg,et al.  Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. , 1992, Journal of hematotherapy.

[60]  L. To,et al.  Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. , 1990, Experimental hematology.

[61]  A. Ho,et al.  Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. , 1990, Experimental hematology.

[62]  J. Villeval,et al.  Effect of recombinant human granulocyte‐macrophage colony stimulating factor on progenitor cells in patients with advanced malignancies , 1990, British journal of haematology.

[63]  F. Herrmann,et al.  Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. , 1989, Blood.

[64]  A. Pileri,et al.  GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR TO HARVEST CIRCULATING HAEMOPOIETIC STEM CELLS FOR AUTOTRANSPLANTATION , 1989, The Lancet.

[65]  W. Piacibello,et al.  Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor. , 1989, The Journal of clinical investigation.

[66]  L. To,et al.  The optimization of collection of peripheral blood stem cells for autotransplantation in acute myeloid leukaemia. , 1989, Bone marrow transplantation.

[67]  J. Villeval,et al.  Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. , 1988, Blood.

[68]  D. Crowther,et al.  In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. , 1988, British Journal of Cancer.

[69]  M. Socinski,et al.  GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN , 1988, The Lancet.

[70]  M. Green,et al.  EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.

[71]  L. To,et al.  High levels of circulating haemopoietic stem cells in very early remission from acute non‐lymphoblastic leukaemia and their collection and cryopreservation , 1984, British journal of haematology.